Peng Ji Ping, Yuan Hai Ming
Beijing Kingmed Center for Clinical Laboratory, Beijing 100010, China.
Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou510330, China.
Yi Chuan. 2018 Sep 20;40(9):779-788. doi: 10.16288/j.yczz.18-120.
Chromosomal microarray analysis (CMA) is a technique for screening numerical and structural abnormalities of chromosomes at the whole genome level. It is a routine tool for pediatric and prenatal genetic diagnoses. It has also been applied to investigate the genetic etiologies of miscarriages. In our study, we used the CMA technology to analyze the chromosomal variations of fetuses from miscarriages at the whole genome level, and to evaluate its clinical applications in studies of miscarriages. The CMA analyses were performed on 2600 miscarriage specimens, of which 2505 specimens (96.35%) were successfully analyzed. Among them, 1021 specimens were analyzed with CytoScan Optima chip; 1211 specimens were analyzed with CytoScan 750K chip; and 273 cases were analyzed with CytoScan HD chip. Chromosomal abnormalities were identified in 967 specimens (38.6%) by these 3 kinds of chips, of which 506 specimens (50.00%) were detected with CytoScan Optima chip; 388 specimens were detected by CytoScan 750K chip (32.00%); and 73 cases (26.74%) were detected in CytoScan HD chip. Among the 967 cases of chromosomal abnormalities, 801 cases (82.83%) were numerical chromosomal abnormalities; 94 cases (9.72%) were structural abnormalities; 56 cases (5.79%) were mosaicisms; and 16 (1.65%) were regions of homozygosity. Our research suggests that CMA is a reliable, robust, and high-resolution technology for genetic diagnosis of miscarriage in clinical practice, which can also provide results as guidance for the risk assessment of assisted fertility.
染色体微阵列分析(CMA)是一种在全基因组水平上筛查染色体数目和结构异常的技术。它是儿科和产前基因诊断的常规工具。它也已被应用于研究流产的遗传病因。在我们的研究中,我们使用CMA技术在全基因组水平上分析流产胎儿的染色体变异,并评估其在流产研究中的临床应用。对2600例流产标本进行了CMA分析,其中2505例标本(96.35%)成功分析。其中,1021例标本用CytoScan Optima芯片进行分析;1211例标本用CytoScan 750K芯片进行分析;273例用CytoScan HD芯片进行分析。通过这3种芯片在967例标本(38.6%)中鉴定出染色体异常,其中用CytoScan Optima芯片检测到506例标本(50.00%);用CytoScan 750K芯片检测到388例标本(32.00%);用CytoScan HD芯片检测到73例(26.74%)。在967例染色体异常病例中,801例(82.83%)为染色体数目异常;94例(9.72%)为结构异常;56例(5.79%)为嵌合体;16例(1.65%)为纯合子区域。我们的研究表明,CMA是临床实践中用于流产基因诊断的一种可靠、强大且高分辨率的技术,它还可以为辅助生殖的风险评估提供结果作为指导。